semaglutide

Overview

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1RA) developed for the treatment of type 2 diabetes and obesity. It is a long-acting analogue of the endogenous incretin hormone GLP-1, engineered with structural modifications — including fatty acid side-chain conjugation and albumin binding — that extend its plasma half-life to approximately one week, enabling once-weekly subcutaneous or once-daily oral dosing. By binding and activating the GLP-1 receptor, semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts centrally on hypothalamic and brainstem circuits to reduce appetite and food intake. These pleiotropic mechanisms collectively produce improvements in glycemic control, body weight, cardiovascular risk factors, and liver metabolic parameters. Semaglutide is approved under the brand names Ozempic (injectable, for type 2 diabetes and cardiovascular risk reduction) and Wegovy (injectable, for chronic weight management), and as Rybelsus (oral tablet, for type 2 diabetes). In 2024–2025, it received regulatory approval as the first GLP-1-based treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-severe fibrosis, further expanding its therapeutic scope.

Mechanistically, semaglutide engages the gut-brain axis through both peripheral and central GLP-1 receptor populations. Peripheral receptors on pancreatic beta cells and enteroendocrine L-cells mediate insulinotropic and satiety signaling, while central nervous system receptors — particularly in the hypothalamus, brainstem, and reward circuitry — modulate dopaminergic pathways, appetite regulation, and reward-related behavior. This broad receptor distribution underpins growing interest in semaglutide beyond metabolic disease, including neurodegenerative conditions, addiction medicine, and cardiovascular protection.

Focus of Latest Publications

Recent publications on semaglutide have focused heavily on real-world effectiveness, safety, and implementation in type 2 diabetes and obesity. Several observational studies evaluated semaglutide in routine care settings, including biosynthetic semaglutide in Pakistan, oral semaglutide in Finland, semaglutide-supported digital weight-loss care in Germany, and 12-month cardiometabolic outcomes in the United Arab Emirates. These reports examined glycaemic control, body weight, lipid profile, liver enzymes, patient-reported outcomes, and treatment persistence, reflecting growing interest in how semaglutide performs outside randomized trials. Related work also assessed semaglutide use in specific clinical contexts such as non-diabetic obesity after acute coronary syndrome, after sleeve gastrectomy, in adolescents with type 1 diabetes and obesity, and in people with HIV, indicating expanding interest in broader cardiometabolic and liver-related applications.

A second cluster of studies addressed semaglutide in combination therapy or comparative effectiveness frameworks. Investigators examined semaglutide with cagrilintide as CagriSema added to basal insulin in type 2 diabetes, semaglutide with native GIP infusion, semaglutide with canagliflozin in early diabetic kidney disease, and GLP-1 receptor agonists alongside SGLT2 inhibitors in real-world diabetes care. Comparative studies also evaluated semaglutide against other GLP-1-based therapies and glucose-lowering drugs for cardiovascular and arrhythmic outcomes, adult-onset seizure risk, and major kidney events, while a network meta-analysis compared semaglutide, tirzepatide, cagrilintide, and CagriSema for overweight and obesity. Across these studies, semaglutide was generally positioned as part of broader incretin-based treatment strategies, with outcomes spanning glycaemic response, weight loss, cardiovascular risk, renal endpoints, and treatment tolerability.

Several publications examined semaglutide in metabolic liver disease and cost-effectiveness contexts. One study evaluated the cost-effectiveness of semaglutide for metabolic dysfunction-associated steatohepatitis with significant fibrosis in the United States, while another discussed semaglutide as part of the evolving therapeutic landscape for MASH and cirrhosis trial innovation. Additional work explored semaglutide’s impact on liver fibrosis score in people with HIV and its role in MASLD-related pathophysiology. These publications collectively highlight semaglutide’s relevance beyond glucose lowering, particularly in cardiometabolic liver disease and health-economic decision-making.

Mechanistic and formulation-focused studies also featured prominently. Preclinical work reported that semaglutide targets muscle mitochondria to regulate glutamine metabolism and improve osteoarthritis-related pain and cartilage damage in mice, while another study found that semaglutide can inhibit initiation of toxic amyloid-β42 aggregation in vitro, suggesting potential relevance to Alzheimer’s disease-related pathways. In formulation science, semaglutide was used as a model peptide in studies of oligomerization and pH-dependent higher-order structure, and new oral delivery systems, including silk nanoparticles and an ionic liquid-based enteric formulation, were developed to improve semaglutide stability, absorption, and bioavailability. Together, these publications show continued interest in semaglutide as both a therapeutic agent and a model compound for understanding peptide behavior, delivery, and broader biological effects.

Key Publications

• NEWJun Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. (Annals of internal medicine, 2026, PMID 42372278): "The workshop concluded that robust RWE is essential for developing value-based coverage policies and optimizing GLP-1RA use."
• NEWJun Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. (The AAPS journal, 2026, PMID 42373916): "The resulting MWhd values were several-fold greater than the corresponding monomeric MW of the glucagon-like peptide-1/2 (GLP-1/2) analogs, insulin analogs, and the monoclonal antibodies (mAbs) infliximab and bevacizumab, indicating varying degrees of oligomerization."
• NEWJun Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. (Diabetes, obesity & metabolism, 2026, PMID 42365987): "To evaluate the real-world effectiveness, safety and patient-reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost-constrained setting."
• NEWJun Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience. (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026, PMID 42362054): "To evaluate the real-world effectiveness of combination therapy with glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2-I) on glucose control in type 2 diabetes (T2D) and to identify clinical predictors of treatment response."
• NEWJun Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. (Diabetes, obesity & metabolism, 2026, PMID 42348222): "We evaluated the cost-effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2-F3 fibrosis."
• NEWJun LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis. (International journal of obesity (2005), 2026, PMID 42332016): "Although the recent FDA approval of Resmetirom and Semaglutide, represents a major therapeutic milestone, its efficacy is limited to a subset of patients."
• NEWJun Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database. (Diabetes, obesity & metabolism, 2026, PMID 42304551): "In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes."
• NEWJun Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis. (iScience, 2026, PMID 42305583): "As a metabolic regulatory drug for lowering body weight, semaglutide has shown additional therapeutic effects in osteoarthritis (OA), but the underlying mechanism requires further investigation."
• NEWJun Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. (Neurology, 2026, PMID 42308439): "We evaluated whether semaglutide initiation is associated with a lower incidence of adult-onset seizure compared with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in adults with type 2 diabetes."
• NEWJun Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response. (Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026, PMID 42295649): "The aim of this study was to evaluate real-world cardiometabolic outcomes and predictors of response following initiation of semaglutide in a tertiary endocrine clinic."